Flexible Facilities: The New Wave of Flexible Biomanufacturing Solutions

IBC’s 2014 Flexible Facilities is your chance to join thought-leaders from biopharma companies, technology providers, CMO's, engineering firms and regulatory groups who will discuss best practices, potential hurdles and creative solutions for the new wave of flexible biomanufacturing solutions that are beginning to emerge. 

LEARN about Novel Facility Design Concepts 

• 100% disposable and hybrid facilities 

• Retrofitting stainless steel to be more flexible 

• Modular systems and plug & play designs 

• Multi-product facilities, open ballrooms and closed systems 

DISCOVER How BARDA and the DOD are Developing Flexible Facilities 

• Emergent’s flexible manufacturing capabilities and facilities 

• Novartis Vaccines and the Holly Springs manufacturing site 

• Kalon Therapeutics and Texas A&M University’s Collaboration 

• Nanotherapeutics flexible manufacturing for Medical Countermeasures 

HEAR about Practical Experiences in Single-use Implementation 

• Single-use in vaccine upstream processes 

• Case study comparing a single use mAb process to a stainless steel process 

• Functionally-closed systems and multi-product facilities 

PREPARE Yourself for Rapid Deployment and Emerging Market Opportunities 

• Biosimilars, flexible systems and emerging markets 

• Establishing manufacturing capacity in BRIC regions 

• Production strategies for pandemics and biothreats 

To learn more, download our full agenda.

Register with priority code FLEX14BLOG to save 20% off of our standard rate. If you have questions about the event, feel free to contact our group manager, Kate Devery (Kdevery@iirusa.com), or visit our webpage. We look forward to seeing you February 24-25 in Berkeley, California! 

Cheers, 

The Flexible Facilities Team 

Opt-in for updates 

Follow us on Twitter  

Flexible Facilities LinkedIn

Share this article with your social network, just click below to share now!

Share |

Biosimilars on the move in Asia

While the United States waits on the ruling of the healthcare act tomorrow, including the fate of Biosimilars in the US, from the Supreme Court tomorrow, many countries in Asia Pacific have are embracing the opportunity of biosimilars in their market.  Many of the countries in Asia Pacific have embraced this more cost effective form of treatment for their growing middle class, who often pays for health insurance out of their pockets.  Countries like China, India and Korea lead the way  in manufacturing and others including Japan, Australia, Singapore and Malaysia have regulations according to Pharma Phorum.  While many of these biosimilars companies have no experience in regulated markets, they are developing and distributing biosimilars to semi-regulated.  This gives them immense amounts of knowledge of the drugs, as the Asian biosimilars market accounts for 25% of the worldwide market.

This September in Boston, the Business of Biosimilars and Generic Drugs will hear from Andrew Shaw, Senior Director, PKDM, Mylan on the topic of globalizing generics and biosimilars.   It could be argued that America is an emerging market in biosimilars, and Shaw will be discussing that.  For more information on Shaw's presentation and the rest of the program, download the agenda here.  If you'd like to join us this September in Boston, register with code XP1786BLOG and save 25% off the standard rate.

What are the benefits of the companies operating in the semi-regulated markets to their business when they decide to expand in to a regulated market, such as the United States or Europe?

Share this article with your social network, just click below to share now!

Share |